Altimmune, Inc. (ALT)
NASDAQ: ALT · IEX Real-Time Price · USD
7.57
+0.10 (1.34%)
At close: Apr 23, 2024, 4:00 PM
7.61
+0.04 (0.53%)
Pre-market: Apr 24, 2024, 4:42 AM EDT
Company Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.
The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus.
The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015.
Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Altimmune, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 59 |
| CEO | Dr. Vipin K. Garg Ph.D. |
Contact Details
Address: 910 Clopper Road, Suite 201s Gaithersburg, Maryland 20878 United States | |
| Phone | (240) 654-1450 |
| Website | altimmune.com |
Stock Details
| Ticker Symbol | ALT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001326190 |
| CUSIP Number | 02155H200 |
| ISIN Number | US02155H2004 |
| Employer ID | 20-2726770 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vipin K. Garg Ph.D. | President, Chief Executive Officer and Director |
| Dr. Matthew Scott Harris AGAF, FCAP, M.D., MS | Chief Medical Officer |
| Raymond M. Jordt M.B.A. | Chief Business Officer |
| Richard I. Eisenstadt M.B.A. | Chief Financial Officer |
| Bertrand Georges Ph.D. | Chief Technology Officer |
| Dr. M. Scot Roberts Ph.D. | Chief Scientific Officer |
| Tony Blandin B.S. | Vice President of Quality and Compliance Management |
| Andrew Shutterly M.S. | Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 27, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 27, 2024 | 10-K | Annual Report |
| Mar 27, 2024 | 8-K | Current Report |
| Mar 5, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |